Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor

Background. Yolk sac tumors of the ovary are generally very responsive to c hemotherapy; however, they are difficult to manage in the setting of platin um resistance where treatment options are limited and outcomes are poorer. Case. We present a 39-year-old woman who had a platinum-resistant yolk sac ovarian tumor. She achieved complete remission on an innovative regimen of docetaxel, gemcitabine, and thalidomide. Conclusion. The combination of docetaxel, gemcitabine, and thalidomide migh t be an active regimen for platinum-resistant ovarian nondysgerminomas and further investigation of this combination is warranted. (C) 2001 Academic P ress.